Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCRT + CAPOX + PD-1 inhibitor vs LCCRT + CAPOX in high-risk MSS/pMMR locally advanced rectal cancer (total neoadjuvant therapy)
ChiCTR2600122961Phase 3Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Capecitabine + oxaliplatin and sugemalimab in rectal cancer (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: 3-year Event-Free Survival Rate (3yEFS%). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Capecitabine + oxaliplatinsugemalimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2600122961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122961.